The University of Chicago Header Logo

Connection

Olatoyosi Odenike to Myeloproliferative Disorders

This is a "connection" page, showing publications Olatoyosi Odenike has written about Myeloproliferative Disorders.
  1. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024 07 09; 8(13):3468-3477.
    View in: PubMed
    Score: 0.699
  2. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):303-309.
    View in: PubMed
    Score: 0.632
  3. Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449.
    View in: PubMed
    Score: 0.545
  4. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
    View in: PubMed
    Score: 0.545
  5. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.523
  6. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2018 11 29; 132(22):2339-2350.
    View in: PubMed
    Score: 0.470
  7. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies. Curr Hematol Malig Rep. 2015 Jun; 10(2):112-7.
    View in: PubMed
    Score: 0.372
  8. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
    View in: PubMed
    Score: 0.279
  9. Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms. Int J Hematol. 2026 Nov; 124(5):640-648.
    View in: PubMed
    Score: 0.201
  10. Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms. Blood Adv. 2026 05 26; 10(10):3746-3755.
    View in: PubMed
    Score: 0.199
  11. Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Adv. 2026 Mar 10; 10(5):1603-1613.
    View in: PubMed
    Score: 0.196
  12. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia. 2022 12; 36(12):2934-2938.
    View in: PubMed
    Score: 0.156
  13. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 12; 36(12):2939-2946.
    View in: PubMed
    Score: 0.155
  14. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
    View in: PubMed
    Score: 0.154
  15. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep. 2014 Dec; 9(4):350-9.
    View in: PubMed
    Score: 0.090
  16. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May; 87(5):562-8.
    View in: PubMed
    Score: 0.075
  17. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 06; 65(6):864-867.
    View in: PubMed
    Score: 0.043
  18. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016 12 08; 9(1):137.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.